Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

384 articles with Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)

• Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime

  3/6/2023

  Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime and announces results of a recently completed market study.

• Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

  2/28/2023

  Windtree Therapeutics, Inc. announced that its preclinical stage drug candidates called SERCA2a Activators were featured in a publication in The Journal of Pharmacology and Experimental Therapeutics entitled “Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.”

• Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference

  2/27/2023

  Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime.

• Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

  2/24/2023

  Windtree Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,583,540, providing expanded patent coverage for istaroxime administration.

• Windtree Therapeutics Announces Reverse Stock Split - February 23, 2023

  2/23/2023

  Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-50 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”).

•  Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants

  1/20/2023

  Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in the aggregate.

• Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance

  12/5/2022

  Windtree Therapeutics, Inc. today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

• Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

  11/14/2022

  Windtree Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.

• Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

  10/25/2022

  Windtree Therapeutics, Inc. reported that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for istaroxime administration.

• Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

  9/28/2022

  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629).

• Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

  9/26/2022

  Windtree Therapeutics, Inc. today reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock (SEISMiC) will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC.

• Windtree to Present at the Ladenburg Thalmann Healthcare Conference

  9/21/2022

  Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.

• Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022.

• 

  Money on the Move: AdvanCell, eTheRNA, Bluejay and More

  8/24/2022

  ​​​​​​​Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.

• Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement

  8/23/2022

  Windtree Therapeutics, Inc. announced it has entered into a global licensing agreement with Lee’s Pharmaceutical Limited, and its affiliate Zhaoke Pharmaceutical Co. Ltd., for the development and commercialization of Windtree’s acute pulmonary pipeline treatments KL4 surfactant and drug/device combination, AEROSURF®, for the treatment of preterm infants with respiratory distress syndrome and other potential applications.

• Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates

  8/11/2022

  Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, reported financial results for the second quarter ended June 30, 2022 and provided key business updates.

• Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

  6/29/2022

  Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders, provided an update to its strategy and pursuit related to partnerships and transactions.

• Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

  5/23/2022

  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today presented data from its positive Phase 2 study of istaroxime in early cardiogenic shock in a late-breaker presentation at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain.

• Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock

  5/16/2022

  Windtree Therapeutics, Inc. announced management will host a conference call and webcast to discuss its istaroxime Phase 2 study in early cardiogenic shock patients following the late-breaker presentation of the data at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain on May 23, 2022.

• Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates

  5/5/2022

  Windtree Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided key business updates.